Enzymotec Ltd (NASDAQ:ENZY) has received an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating. Enzymotec’s rating score has improved by 9.9% in the last 90 days as a result of various analysts’ upgrades and downgrades.
Brokers have set a one year consensus price objective of $9.50 for the company and are anticipating that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also given Enzymotec an industry rank of 189 out of 265 based on the ratings given to related companies.
Several research firms recently issued reports on ENZY. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Jefferies Group reaffirmed a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a report on Thursday, October 19th. Finally, Wells Fargo & Company upped their price objective on shares of Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a report on Monday, October 30th.
Several hedge funds and other institutional investors have recently bought and sold shares of ENZY. Janus Henderson Group PLC bought a new stake in shares of Enzymotec during the 2nd quarter worth $2,350,000. State Street Corp boosted its holdings in shares of Enzymotec by 1.8% during the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after buying an additional 380 shares during the period. Osborn Williams & Donohoe LLC bought a new stake in shares of Enzymotec during the 3rd quarter worth $137,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Enzymotec during the 3rd quarter worth $107,000. 15.73% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Enzymotec Ltd (ENZY) Given Consensus Rating of “Hold” by Brokerages” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://weekherald.com/2017/12/21/enzymotec-ltd-enzy-given-consensus-rating-of-hold-by-brokerages.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.